Sun Pharma ropes in Richard Ascroft as North America CEO

Published On 2025-06-27 07:40 GMT   |   Update On 2025-06-27 07:40 GMT

Mumbai: Sun Pharma has announced the appointment of Richard Ascroft as the new North America (NAM) Chief Executive Officer (CEO).

In a statement shared via LinkedIn, the company said, "We are happy to announce Richard Ascroft has joined Sun Pharma as the new North America (NAM) Chief Executive Officer (CEO). An accomplished leader with an extensive background driving strategic growth through innovation, Richard brings more than three decades of experience to the helm of the U.S. and Canadian businesses."

Ascroft expressed enthusiasm about his new role, stating, "I am honored to lead such a dynamic team committed to advancing Sun's portfolio of generic, innovative and OTC medicines. The North America region is poised to bring new treatments to the market and drive significant growth for business. I look forward to building on our strong foundation, supporting patients throughout their journey and delivering the highest quality generic and innovative medicines to the people we serve."

Prior to joining Sun, Ascroft held leadership roles at Takeda for over nine years, most recently serving as Senior Vice President, Head of US Plasma-Derived Therapies BU. He previously spent more than 22 years at Eli Lilly and Company.

Meanwhile, as previously reported by Medical Dialogues, Sun Pharma also named Kirti Ganorkar as the company's next Managing Director, effective September 1, 2025, succeeding the company's current Managing Director, Dilip Shanghvi. In the new role, Ganorkar will take over the responsibility for the company’s entire business and functions reporting to him.

Read also: Sun Pharma: Kirti Ganorkar to succeed Dilip Shanghvi as new MD

Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult-to-make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and Intermediates.

Read also: Sun Pharma European partner Philogen pulls EMA application for skin cancer drug Nidlegy



Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News